Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.630 -0.040 (-0.86%)
Streaming Delayed Price Updated: 3:42 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
Unusual Options Activity Insight: CureVac ↗
CureVac (NASDAQ:CVAC) shares experienced unusual options ... 
Via Benzinga
News headline image
54 Biggest Movers From Friday ↗
Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc.... 
Via Benzinga
News headline image
Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today ↗
Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector. 
Via InvestorPlace
News headline image
Why Moderna, Novavax And Other COVID-19 Vaccine Stocks Are Plummeting ↗
The COVID-19 pandemic proved to be a boon for many biopharma companies that benefited from their foray into the development of vaccines and/or treatments against the novel... 
Via Benzinga
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
Via FinancialNewsMedia
News headline image
Breaking Down The Inflation Numbers Draws Attention To Oil Prices ↗
Oil futures (/CL) are up 1% this morning ahead of the crude oil inventories report. While the NY Empire State Manufacturing Index was nearly double forecast. However,... 
Via Benzinga
News headline image
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans ↗
CureVac BV has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. 
Via Talk Markets
News headline image
CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans ↗
CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would... 
Via Benzinga
News headline image
Why CureVac's Stock Is Down During Today's Session ↗
CureVac (NASDAQ:CVAC) shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European... 
Via Benzinga
News headline image
CureVac Streamlines European Network for mRNA Product Manufacturing
- CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands - Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 31, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot ↗
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The... 
Via Benzinga
News headline image
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
- Findings in preclinical mouse models provide first direct proof of efficacy of HNF4A mRNA therapeutics in the treatment of liver fibrosis and cirrhosis - Further research aimed at optimizing mRNA... 
From CureVac
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
News headline image
Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines? ↗
It isn't likely. 
Via The Motley Fool
News headline image
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now ↗
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet. 
Via The Motley Fool
News headline image
4 High-Yield Dividend Stocks to Boost Your Dividend Income ↗
Dividends paid by GlaxoSmithKline plc, Vector Group Ltd, Star Group, L.P., and Ennis, Inc translate to high yields at their current price levels. 
Via Talk Markets
News headline image
Boehringer Ingelheim Scraps Lung Cancer Program With CureVac ↗
CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated... 
Via Benzinga
News headline image
Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today ↗
Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering. 
Via InvestorPlace
Topics Economy
News headline image
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update - Continuation of corporate transformation into commercial-ready biopharma company-... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
- Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
26 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares rose 34% to $5.48 in pre-market trading after dropping around 15% on Wednesday. Ensysce Biosciences recently appointed... 
Via Benzinga
News headline image
EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine ↗
EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (... 
Via Benzinga
News headline image
Can CureVac Win Market Share With Only 48% Vaccine Efficacy? ↗
CureVac aims to become one of Europe's big suppliers. 
Via The Motley Fool
News headline image
Unusual Options Activity Insight: CureVac ↗
On Wednesday, shares of CureVac (NASDAQ:CVAC) saw unusual options activity. After the option alert, the stock price moved down to $59.8. Sentiment: BEARISH Option Type: SWEEP... 
Via Benzinga
News headline image
South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters ↗
South Korea is reportedly in talks with mRNA vaccine makers, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), to produce COVID-19 shots in the... 
Via Benzinga
News headline image
Here's Why You Should Avoid CureVac Stock Like the Plague ↗
Funds will not be safe if invested in this coronavirus stock. 
Via The Motley Fool
News headline image
Is CureVac a Bargain Bet on mRNA Vaccine Technology? ↗
CureVac shares have slipped more than 20% on bad news. 
Via The Motley Fool
Topics Cannabis
News headline image
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week ↗
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
Via Talk Markets
News headline image
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week ↗
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.